Denali Therapeutics IncDNLI
Price$20.53Intrinsic value$11.8442% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.6MTTM through 30 Jun 2026
Net Income -$511.5MTTM through 30 Jun 2026
Free Cash Flow -$437.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-15,058.2%
Net Margin-14,191.2%

Returns

-54.8%ROE
-40.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.39x
Net Debt-$987.7Mnet cash position
Cash & Equivalents$201.5M

Quality Metrics

Altman Z-Score2.77
Piotroski F-Score2 / 9
FCF Margin-12,138.1%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $0
Diluted EPS-$2.84TTM
'19'20'21'22'23'24'25
FY2025: $-2.97

Dividend

No dividend

Capital Allocation

Capex Intensity94.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.